Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference

Rhea-AI Summary

Entasis Therapeutics Holdings announced that Dr. Manos Perros, CEO, will present at the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation will be accessible on demand starting January 11 at 6:00 AM ET. Entasis focuses on developing antibacterial products targeting serious infections from multidrug-resistant Gram-negative bacteria, with candidates including sulbactam-durlobactam and zoliflodacin, among others. For more details, visit www.entasistx.com.

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021.

The Company’s presentation will be available on demand starting Monday, January 11^th, 2021 at 6:00 AM ET, to those attending the conference virtually.

About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.

Entasis Company Contact
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com

Investor Relations Contact
James Salierno
The Ruth Group
(646) 536-7028
jsalierno@theruthgroup.com

Media Contact
Annika Parrish
The Ruth Group
(720) 412-9042
aparrish@theruthgroup.com

FAQ

When is the H.C. Wainwright BioConnect 2021 Conference for Entasis (ETTX)?

The conference will be held from January 11-14, 2021.

What time will the Entasis presentation be available during the conference?

The presentation will be available on demand starting January 11, 2021, at 6:00 AM ET.

Who is presenting for Entasis at the BioConnect 2021 Conference?

Dr. Manos Perros, the CEO of Entasis, will present at the conference.

What is the primary focus of Entasis Therapeutics (ETTX)?

Entasis focuses on developing novel antibacterial products for serious infections caused by multidrug-resistant Gram-negative bacteria.

What product candidates are in Entasis's pipeline?

Entasis's pipeline includes sulbactam-durlobactam, zoliflodacin, ETX0282CPDP, and ETX0462.